Plain-English translation of NCT06656676 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a tool called WePrEP—a digital conversation guide designed for transgender women and their healthcare providers. The tool helps both of you talk through options for HIV prevention, including oral medication and injectable cabotegravir (CAB-LA), and decide which method works best for you. The goal is to make sure you get personalized information about the medication that fits your life and your concerns.
Transgender women face higher rates of HIV, and medication can reduce that risk by up to 86%. However, many transgender women worry about how this treatment might interact with gender-affirming hormones, and conversations with doctors about it are often incomplete. This study exists to create a better tool that addresses your specific concerns and helps you make the choice that's right for you.
You likely qualify if…
You likely don't qualify if…
If you join, you'll meet with a healthcare provider at the study site in Denver. You'll either use the new WePrEP tool together with your provider to explore HIV prevention options and discuss which method fits you best, or you'll receive the standard information about available options. Either way, you'll help the research team understand whether this tool makes conversations clearer and helps you feel more confident in your choice.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States